<DOC>
	<DOC>NCT01079806</DOC>
	<brief_summary>The purpose of this study was to evaluate the safety and efficacy of entecavir in pediatric patients with chronic hepatitis B virus infection</brief_summary>
	<brief_title>A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Key Inclusion Criteria Males and females, aged 2 to &lt;18 years Hepatitis B surface antigenpositive Detectable hepatitis B e (HBe) antigen, and no detectable antiHBe antibodies Alanine aminotransferase (ALT) 1.5 to &lt;10 times the upper limit of normal at screening and within 8 to 24 weeks prior to screening Evidence of the presence of hepatitis B virus DNA at least 4 weeks before screening and &gt;100,000 copies/mL at screening Key Exclusion Criteria Any prior therapy with entecavir At least 12 weeks of prior therapy with any nucleoside or nucleotide antiviral agent Therapy with interferon alpha, thymosin alpha, or nucleototide antiviral agents within 24 weeks of screening Coinfection with HIV, hepatitis C virus, or hepatitis D virus Decompensated liver disease Liver transplant recipients Other forms of acute and chronic conditions which may cause increased ALT levels Children who were breastfed while their mothers received lamivudine or whose mothers received lamivudine during pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>